1. Home
  2. MERC vs ACOG Comparison

MERC vs ACOG Comparison

Compare MERC & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercer International Inc.

MERC

Mercer International Inc.

HOLD

Current Price

$2.07

Market Cap

106.5M

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.94

Market Cap

115.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MERC
ACOG
Founded
1968
2000
Country
Canada
Canada
Employees
N/A
N/A
Industry
Paper
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
106.5M
115.5M
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
MERC
ACOG
Price
$2.07
$5.94
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$3.00
$18.00
AVG Volume (30 Days)
737.4K
104.1K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
7.35%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,906,971,000.00
$7,427,199.00
Revenue This Year
N/A
N/A
Revenue Next Year
$12.53
$132.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.48
$3.75
52 Week High
$8.28
$11.54

Technical Indicators

Market Signals
Indicator
MERC
ACOG
Relative Strength Index (RSI) 56.41 55.95
Support Level $1.98 $5.61
Resistance Level $2.15 $6.20
Average True Range (ATR) 0.12 0.57
MACD 0.03 0.10
Stochastic Oscillator 51.82 74.00

Price Performance

Historical Comparison
MERC
ACOG

About MERC Mercer International Inc.

Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: